Pegloticase for treatment of tophaceous polyarticular gout.

Abstract

This is a case report of a patient with treatment resistant gout who was prescribed pegloticase and developed a severe reaction. A 30-year-old Hawaiian-Filipino man presented with a nine-year history of gout that progressed from episodic monoarticular arthritis, treated with aspiration and corticosteroid injections, to more aggressive disease with more frequent attacks requiring escalation of therapy. He was treated with systemic corticosteroids, colchicine and nonsteroidal anti-inflammatory drugs, but then required allopurinol. Despite aggressive therapy, the patient continued to have hyperuricemia and tophi developed even after treatment with febuxostat and probenicid. The patient became wheel chair bound due to his pain and, at that point, the decision was made to initiate treatment with pegloticase. The patient initially experienced significant improvement with treatment; however, he soon began to have elevation in his serum uric acid levels and developed a severe reaction during treatment.

• Authors: Rebecca M Seifried, Jefferson Roberts
• Journal: Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health (Hawaii J Med Public Health) Vol. 72 Issue 7 Pg. 220-3 (Jul 2013) ISSN: 2165-8242 [Electronic] United States
• PMID: 23901393 (Publication Type: Case Reports, Journal Article)

Chemical References

• Gout Suppressants
• Thiazoles
• Febuxostat
• Uric Acid
• Polyethylene Glycols
• Urate Oxidase
• Pegloticase

Topics

• Adult
• Arthritis, Gouty (blood, complications, drug therapy)
• Febuxostat
• Gout Suppressants (therapeutic use)
• Humans
• Male
• Polyethylene Glycols (therapeutic use)
• Thiazoles (therapeutic use)
• Urate Oxidase (therapeutic use)
• Uric Acid (blood)